Q-omics provides the consensus-scored KYAT1 profile across patient tissues and cancer cell-line models. KYAT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KYAT1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, KYAT1 RNA expression shows 19,260 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where KYAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KYAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KYAT1 survival associations across molecular data types. KYAT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KYAT1 RNA expression–survival associations across cancer types. High KYAT1 expression shows unfavorable associations in ACC and COAD, but favorable associations in LGG, KIRC, READ and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KYAT1 RNA expression.
This table summarizes KYAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KYAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KYAT1 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LIHC, READ and LUSC. The COAD box plot shows higher KYAT1 RNA expression in tumor versus normal tissue (log2 FC = +1.352, t-test p < 0.001).
This table shows molecular features associated with KYAT1 in patient tissues and cancer cell lines. In patient samples, KYAT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KYAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
